1.24Open1.24Pre Close0 Volume582 Open Interest2.50Strike Price0.00Turnover250.52%IV-4.13%PremiumJan 17, 2025Expiry Date1.29Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8000Delta0.3740Gamma0.90Leverage Ratio-0.0044Theta-0.0011Rho-0.72Eff Leverage0.0008Vega
Editas Medicine Stock Discussion
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Thursday, 12th December at 4:00 pm
• Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues:
◦ Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell...
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
No comment yet